Restenosis News and Research

RSS

Restenosis means the reoccurrence of stenosis, a narrowing of a blood vessel, leading to restricted blood flow. Restenosis usually pertains to an artery or other large blood vessel that has become narrowed, received treatment to clear the blockage and subsequently become renarrowed. This is usually restenosis of an artery, or other blood vessel, or possibly a vessel within an organ.

Everolimus-eluting stent and SES are equally effective for PCI patients

The second generation drug-eluting stent, everolimus-eluting stent (EES), has consistently demonstrated superior clinical outcomes in randomised controlled trials over the first generation drug-eluting stent, paclitaxel-eluting stent.

29 Aug 2011

itm FlowMedical initiates Rhenium-PTA therapy clinical trial in PAOD

itm FlowMedical GmbH announced the start of OPEN-188 clinical trial. It will compare itm Rhenium-PTA, a therapy for the prevention of restenosis in peripheral vessels, to a regular PTA, the standard therapy for the treatment of PAOD.

23 Aug 2011

Coronary stent implantation safe, feasible for infants or toddlers with ACS

Percutaneous coronary intervention (PCI) is not a generally accepted option for infants or toddlers with acute coronary syndrome. However, a new report published in the August issue of Catheterization and Cardiovascular Interventions, a journal of The Society for Cardiovascular Angiography and Interventions (SCAI), found coronary stent implantation to be a feasible and safe palliative option for children fifteen months and younger.

22 Aug 2011

OrbusNeich's Genous Stent safe, effective for patients at high risk of restenosis

OrbusNeich today announced that the that the company's Genous Stent showed no significant difference in the rate of target vessel failure (TVF) at two years compared to the Taxus Liberte™ paclitaxel-eluting stent in patients with de novo coronary artery lesions carrying a high risk for restenosis.

17 Aug 2011

FDA approves Abbott's RX Herculink Elite Renal Stent System for renal artery stenosis

Abbott today announced it has received U.S. Food and Drug Administration (FDA) approval for the RX Herculink Elite® Renal Stent System for the treatment of renal artery stenosis (narrowing of the main arteries supplying blood to the kidneys) in patients with uncontrolled hypertension (high blood pressure).

10 Aug 2011

Enrollment commences in Lutonix LEVANT 2 drug-coated balloon IDE trial for PAD

Lutonix today announced the first patient enrolled in the LEVANT 2 clinical trial, a global, multicenter, randomized trial evaluating the safety and efficacy of the Moxy™ Drug Coated Balloon compared to a standard angioplasty balloon for the treatment of peripheral arterial disease (PAD). The first case was performed at St. John's Hospital in Springfield, IL by Dr. Jeff Goldstein.

25 Jul 2011

Clinipace Worldwide selected to manage Spectranetics' cardiovascular device clinical study

Clinipace Worldwide, a global digital clinical research organization (dCRO), announced today that Spectranetics Corporation, a developer, manufacturer, marketer and distributer of single-use medical devices used in minimally invasive procedures within the cardiovascular system, has selected Clinipace to manage all aspects of a pivotal cardiovascular device clinical study that will serve as the basis for 510(k) notice submission.

20 Jul 2011

BIOTRONIK begins comparative study of ORSIRO stent with Abbott's XIENCE PRIME stent

BIOTRONIK announced today the start of an international study comparing the company's ORSIRO sirolimus-eluting coronary stent with Abbott Laboratory's XIENCE PRIME everolimus-eluting coronary stent. The first implantations in the study, called BIOFLOW-II, took place in Europe last week.

14 Jul 2011

Enrollment complete in Boston Scientific's Adapt Monorail Carotid Stent System trial

Boston Scientific Corporation has completed patient enrollment in the ASTI post-market clinical follow-up study designed to evaluate its Adapt Monorail Carotid Stent System in combination with its FilterWire EZ Embolic Protection System for treatment of carotid artery disease in patients at high risk for carotid surgery.

13 Jul 2011

Spectranetics initiates enrollment in EXCITE clinical trial against femoropopliteal IRS

Spectranetics Corporation today announces the first patient enrollment in the EXCITE ISR (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis) clinical trial.

27 Jun 2011

Genetic biomarker may help identify patients at increased risk of bypass surgery

Outcomes of bypass surgery to repair blocked arteries in the legs tend to be better in the roughly one-in-five people who have inherited a specific genetic variation from both parents, according to a study presented at the late-breaking clinical trials session of the Vascular Annual Meeting in Chicago on June 18, 2011.

20 Jun 2011

FDA approves Abbott's XIENCE nano stent for treatment of coronary artery disease in small vessels

Abbott today announced it has received U.S. Food and Drug Administration approval for the XIENCE nano Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease in small vessels.

25 May 2011

Elixir DESyne Drug Eluting Coronary Stent System granted CE Mark approval

Elixir Medical Corporation, a developer of product platforms combining state-of-the-art medical devices with advanced pharmaceuticals, announced that it has received CE Mark for its DESyne Drug Eluting Coronary Stent System for the treatment of coronary artery disease.

23 May 2011

Clinical data of Medtronic's Resolute drug-eluting stent in diabetes presented at EuroPCR meeting

For patients with both heart disease and diabetes who took part in a pooled series of rigorous clinical trials, the Resolute drug-eluting stent from Medtronic, Inc., provided remarkably safe and effective outcomes, according to the results of several studies presented today at EuroPCR, a major international meeting for cardiac and vascular specialists.

From Medtronic 18 May 2011

Medtronic to present clinical trial data of IN.PACT drug-eluting balloon technology at EuroPCR meeting

A global leader in advancing the treatment of cardiovascular disease through innovative medical technology, Medtronic, Inc. today announced recent milestones in its clinical program for the IN.PACT drug-eluting balloon technology.

From Medtronic 17 May 2011

MEDRAD's Cotavance catheter with Paccocath technology receives European CE Mark approval

MEDRAD, INC., a business of Bayer HealthCare, today announced it has received CE Mark for its Cotavance Paclitaxel Coated Balloon Angioplasty Catheter with Paccocath technology.

17 May 2011

Spectranetics revenue increases 5% to $30.4 million for first quarter 2011

Spectranetics Corporation today reported financial results for the quarter ended March 31, 2011.

27 Apr 2011

Boston Scientific initiates clinical enrollment for INNOVA Self-Expanding Bare-Metal Stent System trial

Boston Scientific Corporation today announced the start of patient enrollment in the SuperNOVA clinical trial, an international, prospective, single-arm, non-randomized trial evaluating the safety and effectiveness of the INNOVA™ Self-Expanding Bare-Metal Stent System in patients with stenosis of the superficial femoral artery (SFA) or proximal popliteal artery (PPA).

6 Apr 2011

Improved technology is improving outcomes for cardiac stent patients

While coronary artery bypass surgery has long been the standard treatment for patients with the most extensive forms of coronary artery disease, the results of a recent study by an international team of researchers suggests that advances in technology appear to be narrowing the "benefit gap" between the two approaches. The results of the study appear in the March 17, 2011 issue of the New England Journal of Medicine.

28 Mar 2011

Molecular pharmacologist receives AACR Award for cancer research

Susan Band Horwitz, Ph.D., will receive the Eighth Annual AACR Award for Lifetime Achievement in Cancer Research. Horwitz conducted pioneering research by discovering the mechanism of action of the chemotherapeutic drug paclitaxel, which prompted the development of this drug as an important therapy for many common solid tumors, including ovarian, breast, and lung carcinomas.